Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WHSPR
- Development stage
- Unknown
- Lead developer
- Solésence
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
WHSPR is a proprietary delivery platform technology developed by Solésence, Inc. designed to stabilize and deliver high concentrations of allantoin, a well-known skin protectant. The technology is particularly effective in anhydrous product formats such as serums, balms, and face or lip oils, which are often challenging for traditional allantoin formulations. Clinical studies have demonstrated that WHSPR-enabled products provide statistically significant improvements in skin barrier recovery, barrier strength, hydration, and reduction of redness. It is utilized across skincare, suncare, and color cosmetics, supporting FDA OTC monograph claims for skin and lip protection.
- Brand names
- WHSPR
Beyond the preview
Go deeper on WHSPR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WHSPR.